An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Willow Health Services recently decided to stop making certain claims about its compounded semaglutide products after a review by the National Advertising Division (NAD). The NAD is a self-regulatory group that looks at whether advertising is misleading. Willow’s move was voluntary and came after the NAD reopened a matter about the company’s claims. Semaglutide is the active ingredient in drugs you’ve probably heard of, like Ozempic and Wegovy. In plain terms, it copies a natural gut hormone that helps you feel full and slows how fast your stomach empties, which can lower blood sugar and help with weight loss. “Compounded” semaglutide means it was mixed up by a pharmacy rather than made and approved as a commercial drug by a big manufacturer and regulators. The news here isn’t about new science or a clinical trial. It’s about advertising and claims: the NAD looked at what Willow was saying about its compounded semaglutide products and, after reopening the case, the company chose to stop making those particular claims. The report doesn’t say Willow admitted the claims were false; it says the company voluntarily discontinued them. There’s no data presented in the snippet about effectiveness, safety, or patient outcomes from Willow’s products—so this is a regulatory/marketing story, not new medical evidence. Why this matters to you depends on whether you’re thinking about using semaglutide or buying compounded versions. Compounded drugs can sometimes be useful when a patient needs a specific dose or formulation that approved products don’t provide. But the quality, consistency, and the claims around compounded products are less tightly controlled than for approved medicines. If a company is being asked to stop certain advertising claims, that could signal you should ask more questions about what’s actually proven for any compounded product you’re considering. Caveats: this report doesn’t tell us that compounded semaglutide is unsafe or ineffective—only that advertising claims were challenged and then dropped. Compounded medicines can carry risks like incorrect dosing or contamination if not made properly. Also, the NAD is not a government regulator that issues safety bans; it’s an industry body that evaluates advertising. If you’re thinking about semaglutide for weight loss or diabetes, the clearest path is to talk with a licensed clinician and consider authorized, approved products that have been tested in clinical trials. Bottom line: Willow stopped certain advertising claims about its compounded semaglutide after a review by the National Advertising Division, which raises red flags about the way the product was being presented—but it doesn’t by itself prove the drug is unsafe or ineffective.
Source: The Manila Times